For example, the FLT3-N676K mutation disables binding of midostaurin (PKC412) (Heidel et al. 2006), which is approved for the treatment of AML with mutant FLT3 (Majothi et al. 2020; Perl 2019). This evidence concerns the gene FLT3 and acute myeloid leukemia.